Business Wire

CGTN: Super Virus – COVID-19: How We Got Here

11.6.2020 18:12:00 EEST | Business Wire | Press release

Share

The novel coronavirus has so far claimed over 400,000 lives worldwide, according to John Hopkins University. No one knows how dangerous the virus really is and how long the pandemic will last.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005636/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Super Virus COVID-19 (Photo: Business Wire)

To present readers with a clear picture of how we got here, CGTN portrayed seven* hard-hit countries in an interactive Super Virus. These countries – China, South Korea, the U.S., Germany, France, Italy and the UK – all reported initial confirmed cases at an early stage of the outbreak and all have their relatively mature healthcare systems strained in the fight against it. But their different policy measures have resulted in varied outcomes.

While it’s far too early to draw simple conclusions, the policy measures taken in each country do require scrutiny. The interactive takes a comparative approach in visualizing when and how quickly these measures were enacted over the course of the pandemic. CGTN compiled and analyzed data in the realms of testing, which is crucial to early detection, preventive measures including economic shutdowns and cancellation of public gatherings, as well as the development of clinical methods and the ultimate panacea – an effective vaccine.

Actions taken by countries in regards to testing in the early days appear to have contributed to huge differences down the road. Italy started out with mass testing but then scaled back to only focus on patients who were symptomatic. As the outbreak worsened in Britain, it focused testing and medical resources on critically ill patients.

South Korea and the U.S. reported their first coronavirus cases at almost the same time. But their governments’ attitudes toward testing amid the outbreak couldn’t be more different.

A week after South Korea reported its first case, its health department gathered more than 20 pharmaceutical companies to secure a testing method for COVID-19 that was settled upon eight days later. But weeks after the coronavirus landed in the U.S., there continued to be frustration over shortcomings in diagnostic test distribution and flawed test kits. First there was an outcry over the red tape in getting COVID-19 testing kits approved, then came confusion over who could get a test.

As for travel restrictions, border controls of different types were adopted by many of the six countries. Measures ranged from health checks at the airport to travel warnings and restrictions to quarantining returning overseas travelers. A latecomer to border controls, China didn’t implement restrictions until the end of March when global cases had already exploded.

Such a policy came with extreme measures in certain countries. The Trump administration suspended immigration to the U.S. for 60 days in the name of protecting domestic workers as unemployment hit a record high amid the coronavirus. But this policy left numerous families and businesses reeling instead of boosting employment.

Early-stage border controls also contributed to one problem: Most Western countries neglected prevention and control within their borders.

Restrictions on the movement of peoples within national borders were implemented with varying degrees of effectiveness. Most of the six countries, for instance, adopted stay-at-home orders ahead of lockdowns, except China. In the early morning of January 23, over 20 days after the first known cluster of cases was reported, Wuhan launched a severe lockdown, barring all cars, trains, planes in and out, which lasted 76 days.

In Italy, where similar measures were taken in the country’s northern Lombardy and Veneto – that, combined, makes up 30 percent of the Italian economy, residents were subjected to mandatory home quarantines with all non-essential businesses closed. Meanwhile, some of the other countries like the U.S. and the UK skipped imposing mandatory quarantines in the early stages due to various reasons.

COVID-19 caught the whole world off guard, exposing how we are underprepared in the face of a pandemic of such a scale and scope. The virus has grievously overburdened even the world’s best healthcare systems, with all the seven countries suffering from a dearth of medical professionals and supplies. Doctors and nurses continue to face the danger of being infected, and the psychological burden that they may spread the disease to other patients, or lost their jobs when back from the frontline.

The coronavirus is also not an equal offender — it has disproportionately affected historically marginalized populations. Rates of infection and death from the coronavirus are higher for African and Native Americans, who are on average poorer than their white counterparts. When it comes to age, the elderly makes up a sizable portion of all deaths, due to complications from the coronavirus on top of other conditions. Indigenous peoples are also experiencing higher rates of infection than the national averages of the countries they reside in. In Europe, the Roma live in overcrowded shantytowns, making them particularly affected by the outbreak given the lack of sanitary living conditions.

While outbreaks continue in many of these countries with advanced medical development, the future doesn’t seem to be defined by doom and gloom. Since the outbreak began in January, hundreds of universities, pharmaceutical companies and international organizations have participated in some 320 trials looking into various treatments for COVID-19. Given how divisive COVID-19 has been, the immense scale of this endeavor calls for cooperation across nations, organizations and societies. While time is the best asset for a rapidly spreading pandemic, it is not too late to cultivate this spirit of cooperation.

* The mobile version of the interactive only focuses on six countries for optimal user experience.

Original article: https://news.cgtn.com/news/2020-06-09/Super-Virus-COVID-19-How-we-got-here--Ra9s4L7rBC/index.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX ® , a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain15.9.2026 14:30:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to over one million Americans. During the 2026 Winter Games in Milano Cortina, Lindsey suffered a serious crash during her downhill race. The fall resulted in multiple injuries that required immediate surgery and several additional procedures. Now, Lindsey is sharing her story and her personal experience treating her moderate-to-severe acute pain with JOURNAVX. “I have experienced countless injuries throughout my career, and I’m no stranger to the pain that comes along with them. After my injury at the 2026 Olympic Winter Games,

Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 14:00:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat Gaurav and Executive Vice President, EMEA, Fabienne Cêtre, will open the mainstage with an exploration of the market forces reshaping global supply chains and how operational orc

Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 14:00:00 EEST | Press release

Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring.” — Rasmus Madsen, CEO, Cebreo Medical Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit complianc

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long

NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release

NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye